Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration
- PMID: 17994014
- DOI: 10.1038/nn2011
Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration
Abstract
Expansion of the polyglutamine (polyQ) tract in human TATA-box binding protein (TBP) causes the neurodegenerative disease spinocerebellar ataxia 17 (SCA17). It remains unclear how the polyQ tract regulates normal protein function and induces selective neuropathology in SCA17. We generated transgenic mice expressing polyQ-expanded TBP. These mice showed weight loss, progressive neurological symptoms and neurodegeneration before early death. Expanded polyQ tracts reduced TBP dimerization but enhanced the interaction of TBP with the general transcription factor IIB (TFIIB). In SCA17 transgenic mice, the small heat shock protein HSPB1, a potent neuroprotective factor, was downregulated, and TFIIB occupancy of the Hspb1 promoter was decreased. Overexpression of HSPB1 or TFIIB alleviated mutant TBP-induced neuritic defects. These findings implicate the polyQ domain of TBP in transcriptional regulation and provide insight into the molecular pathogenesis of SCA17.
Similar articles
-
The indole compound NC009-1 inhibits aggregation and promotes neurite outgrowth through enhancement of HSPB1 in SCA17 cells and ameliorates the behavioral deficits in SCA17 mice.Neurotoxicology. 2018 Jul;67:259-269. doi: 10.1016/j.neuro.2018.06.009. Epub 2018 Jun 21. Neurotoxicology. 2018. PMID: 29936316
-
Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity.J Biol Chem. 2008 Mar 28;283(13):8283-90. doi: 10.1074/jbc.M709674200. Epub 2008 Jan 24. J Biol Chem. 2008. PMID: 18218637 Free PMC article.
-
Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.Brain. 2011 Jul;134(Pt 7):1943-58. doi: 10.1093/brain/awr146. Brain. 2011. PMID: 21705419 Free PMC article.
-
Molecular Mechanisms and Therapeutics for SCA17.Neurotherapeutics. 2019 Oct;16(4):1097-1105. doi: 10.1007/s13311-019-00762-z. Neurotherapeutics. 2019. PMID: 31317427 Free PMC article. Review.
-
TATA-binding protein in neurodegenerative disease.Neuroscience. 2005;133(4):863-72. doi: 10.1016/j.neuroscience.2005.03.024. Neuroscience. 2005. PMID: 15916858 Review.
Cited by
-
Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.Neurotherapeutics. 2019 Apr;16(2):263-286. doi: 10.1007/s13311-018-00696-y. Neurotherapeutics. 2019. PMID: 30607747 Free PMC article. Review.
-
Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.J Biol Chem. 2010 Apr 2;285(14):10653-61. doi: 10.1074/jbc.M109.083287. Epub 2010 Feb 9. J Biol Chem. 2010. PMID: 20145253 Free PMC article.
-
Cerebellum-enriched protein INPP5A contributes to selective neuropathology in mouse model of spinocerebellar ataxias type 17.Nat Commun. 2020 Feb 27;11(1):1101. doi: 10.1038/s41467-020-14931-8. Nat Commun. 2020. PMID: 32107387 Free PMC article.
-
Nuclear accumulation of polyglutamine disease proteins and neuropathology.Mol Brain. 2009 Jul 3;2:21. doi: 10.1186/1756-6606-2-21. Mol Brain. 2009. PMID: 19575804 Free PMC article. Review.
-
Evolution and function of CAG/polyglutamine repeats in protein-protein interaction networks.Nucleic Acids Res. 2012 May;40(10):4273-87. doi: 10.1093/nar/gks011. Epub 2012 Jan 28. Nucleic Acids Res. 2012. PMID: 22287626 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous